Compare AES Corp (AES) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs State Street SPDR S&P Biotech ETF — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: AES Corp pays a 4.79% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AES Corp nearer its low. Which is the better fit depends on your goals.
| AES | XBI | |
|---|---|---|
Market Cap | $10.49B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $17.28 | $164.28 |
52-Week Low | $12.51 | $86.92 |
Enterprise Value | $40.75B | — |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.725, down 0.03% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and a low P/E of 5.51. Recent news highlights a pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, alongside a quarterly dividend of $0.17595 per share.
The stock offers a high dividend yield and appears undervalued based on earnings, but faces risks from the acquisition's regulatory scrutiny and a recent earnings miss. Upside is capped near the $15 buyout price if the deal closes, while downside exists if approvals fail. Analyst sentiment is mixed with no sell ratings but a majority on hold.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
